FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced positive results from its 20 patient U.S. feasibility clinical trial assessing the safety and efficacy of GEM OS1™ Bone Graft in foot and ankle fusion indications. The randomized, prospective, controlled study, conducted in accordance with an approved Investigation Device Exemption (IDE) from the US FDA, is designed to compare GEM OS1 versus autogenous bone graft (ABG), which is bone harvested from the patient’s own body and is currently considered the standard of care. Radiographic, functional and pain assessments indicated that GEM OS1 treatment is as effective as autograft for the stimulation of bone healing (fusion), without the pain and morbidity associated with the harvesting of the autograft.
